Travellers familiar with Tapazole from North America or Southeast Asia are unlikely to encounter the same brand elsewhere — it is registered in only six countries. The footprint spans an unusual mix of markets, including the United States, Canada, Italy, Lebanon, the Philippines, and Thailand, rather than a single tight regional cluster.
The active ingredient in Tapazole is thiamazole, classified as an antithyroid agent within the broader category of endocrine and thyroid therapy. Thiamazole-containing products are prescribed in the management of hyperthyroidism and thyrotoxicosis, in the medical management of goiter, and in the preparation of patients for thyroidectomy or other thyroid-related surgery. The structured indication block on this page details the registered uses recognised by the regulators in each of the markets where Tapazole is sold.
Outside those six countries, the Tapazole brand itself may be unfamiliar — but thiamazole, also known internationally as methimazole, is one of the standard antithyroid molecules and circulates worldwide under several other brand names. A patient who has been stabilised on Tapazole and is now travelling or relocating will, in most regulated markets, find a thiamazole-containing equivalent available locally, although the brand name and packaging will likely be different.
A local pharmacist familiar with the regional formulary is well placed to identify the appropriate equivalent product, and other antithyroid molecules also exist within the same therapeutic class for situations where thiamazole itself is not the right fit. Antithyroid therapy is closely monitored and individualised, so any change of brand, molecule, or regimen should be made in consultation with the prescribing healthcare provider rather than improvised at the pharmacy counter.
Symptoms may include nausea, vomiting, epigastric distress, headache, fever, joint pain, pruritus, and edema. Aplastic anemia (pancytopenia) or agranulocytosis may be manifested in hours to days. Less frequent events are hepatitis, nephrotic syndrome, exfoliative dermatitis, neuropathies, and CNS stimulation or depression. No information is available on the median lethal dose of the drug or the concentration of methimazole in biologic fluids associated with toxicity and/or death.
TreatmentTo obtain up-to-date information about the treatment of overdose, a good resource is your certified Regional Poison Control Center. In managing overdosage, consider the possibility of multiple drug overdoses, interaction among drugs, and unusual drug kinetics in the patient.
In the event of an overdose, appropriate supportive treatment should be initiated as dictated by the patient's medical status.
TAPAZOLE is contraindicated in the presence of hypersensitivity to the drug or any of the other product components.
Major adverse reactions (which occur with much less frequency than the minor adverse reactions) include inhibition of myelopoieses (agranulocytosis, granulocytopenia, thrombocytopenia, and aplastic anemia), drug fever, a lupus-like syndrome, insulin autoimmune syndrome (which can result in hypoglycemic coma), hepatitis (jaundice may persist for several weeks after discontinuation of the drug), periarteritis, and hypoprothrombinemia. Nephritis occurs very rarely.
Minor adverse reactions include skin rash, urticaria, nausea, vomiting, epigastric distress, arthralgia, paresthesia, loss of taste, abnormal loss of hair, myalgia, headache, pruritus, drowsiness, neuritis, edema, vertigo, skin pigmentation, jaundice, sialadenopathy, and lymphadenopathy.
TAPAZOLE is indicated:
See WARNINGS
If TAPAZOLE is used during the first trimester of pregnancy or if the patient becomes pregnant while taking this drug, the patient should be warned of the potential hazard to the fetus.
In pregnant women with untreated or inadequately treated Graves' disease, there is an increased risk of adverse events of maternal heart failure, spontaneous abortion, preterm birth, stillbirth and fetal or neonatal hyperthyroidism.
Because methimazole crosses placental membranes and can induce goiter and cretinism in the developing fetus, hyperthyroidism should be closely monitored in pregnant women and treatment adjusted such that a sufficient, but not excessive, dose be given during pregnancy. In many pregnant women, the thyroid dysfunction diminishes as the pregnancy proceeds; consequently, a reduction of dosage may be possible. In some instances, anti-thyroid therapy can be discontinued several weeks or months before delivery.
Due to the rare occurrence of congenital malformations associated with methimazole use, it may be appropriate to use an alternative anti-thyroid medication in pregnant women requiring treatment for hyperthyroidism particularly in the first trimester of pregnancy during organogenesis.
Given the potential maternal adverse effects of propylthiouracil (e.g., hepatotoxicity), it may be preferable to switch from propylthiouracil to TAPAZOLE for the second and third trimesters.
Methimazole crosses the placental membranes and can cause fetal harm, when administered in the first trimester of pregnancy. Rare instances of congenital defects, including aplasia cutis, craniofacial malformations (facial dysmorphism; choanal atresia), gastrointestinal malformations (esophageal atresia with or without tracheoesophageal fistula), omphalocele and abnormalities of the omphalomesenteric duct have occurred in infants born to mothers who received TAPAZOLE in the first trimester of pregnancy. If TAPAZOLE is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be warned of the potential hazard to the fetus.
Because of the risk for congenital malformations associated with use of TAPAZOLE in the first trimester of pregnancy, it may be appropriate to use other agents in pregnant women requiring treatment for hyperthyroidism. If TAPAZOLE is used, the lowest possible dose to control the maternal disease should be given.
AgranulocytosisAgranulocytosis is potentially a life-threatening adverse reaction of TAPAZOLE therapy. Patients should be instructed to immediately report to their physicians any symptoms suggestive of agranulocytosis, such as fever or sore throat. Leukopenia, thrombocytopenia, and aplastic anemia (pancytopenia) may also occur. The drug should be discontinued in the presence of agranulocytosis, aplastic anemia (pancytopenia), ANCA-positive vasculitis, hepatitis, or exfoliative dermatitis and the patient's bone marrow indices should be monitored.
Liver ToxicityAlthough there have been reports of hepatotoxicity (including acute liver failure) associated with TAPAZOLE, the risk of hepatotoxicity appears to be less with methimazole than with propylthiouracil, especially in the pediatric population. Symptoms suggestive of hepatic dysfunction (anorexia, pruritis, right upper quadrant pain, etc.) should prompt evaluation of liver function (bilirubin, alkaline phosphatase) and hepatocellur integrity (ALT, AST). Drug treatment should be discontinued promptly in the event of clinically significant evidence of liver abnormality including hepatic transaminase values exceeding 3 times the upper limit of normal.
HypothyroidismTAPAZOLE can cause hypothyroidism necessitating routine monitoring of TSH and free T4 levels with adjustments in dosing to maintain a euthyroid state. Because the drug readily crosses placental membranes, methimazole can cause fetal goiter and cretinism when administered to a pregnant woman. For this reason, it is important that a sufficient, but not excessive, dose be given during pregnancy (see PRECAUTIONS, Pregnancy).
PRECAUTIONS GeneralPatients who receive methimazole should be under close surveillance and should be cautioned to report immediately any evidence of illness, particularly sore throat, skin eruptions, fever, headache, or general malaise. In such cases, white-blood-cell and differential counts should be obtained to determine whether agranulocytosis has developed. Particular care should be exercised with patients who are receiving additional drugs known to cause agranulocytosis.
Laboratory TestsBecause methimazole may cause hypoprothrombinemia and bleeding, prothrombin time should be monitored during therapy with the drug, especially before surgical procedures. Thyroid function tests should be monitored periodically during therapy. Once clinical evidence of hyperthyroidism has resolved, the finding of a rising serum TSH indicates that a lower maintenance dose of TAPAZOLE should be employed.
Carcinogenesis, Mutagenesis, Impairment Of FertilityIn a 2 year study, rats were given methimazole at doses of 0.5, 3, and 18 mg/kg/day. These doses were 0.3, 2, and 12 times the 15 mg/day maximum human maintenance dose (when calculated on the basis of surface area). Thyroid hyperplasia, adenoma, and carcinoma developed in rats at the two higher doses. The clinical significance of these findings is unclear.
Pregnancy Pregnancy Category DSee WARNINGS
If TAPAZOLE is used during the first trimester of pregnancy or if the patient becomes pregnant while taking this drug, the patient should be warned of the potential hazard to the fetus.
In pregnant women with untreated or inadequately treated Graves' disease, there is an increased risk of adverse events of maternal heart failure, spontaneous abortion, preterm birth, stillbirth and fetal or neonatal hyperthyroidism.
Because methimazole crosses placental membranes and can induce goiter and cretinism in the developing fetus, hyperthyroidism should be closely monitored in pregnant women and treatment adjusted such that a sufficient, but not excessive, dose be given during pregnancy. In many pregnant women, the thyroid dysfunction diminishes as the pregnancy proceeds; consequently, a reduction of dosage may be possible. In some instances, anti-thyroid therapy can be discontinued several weeks or months before delivery.
Due to the rare occurrence of congenital malformations associated with methimazole use, it may be appropriate to use an alternative anti-thyroid medication in pregnant women requiring treatment for hyperthyroidism particularly in the first trimester of pregnancy during organogenesis.
Given the potential maternal adverse effects of propylthiouracil (e.g., hepatotoxicity), it may be preferable to switch from propylthiouracil to TAPAZOLE for the second and third trimesters.
Nursing MothersMethimazole is present in breast milk. However, several studies found no effect on clinical status in nursing infants of mothers taking methimazole. A long-term study of 139 thyrotoxic lactating mothers and their infants failed to demonstrate toxicity in infants who are nursed by mothers receiving treatment with methimazole. Monitor thyroid function at frequent (weekly or biweekly) intervals.
Pediatric UseBecause of postmarketing reports of severe liver injury in pediatric patient treated with propylthiouracil, TAPAZOLE is the preferred choice when an antithyroid drug is required for a pediatric patient (see DOSAGE AND ADMINISTRATION).
TAPAZOLE is administered orally. The total daily dosage is usually given in 3 divided doses at approximately 8-hour intervals.
AdultThe initial daily dosage is 15 mg for mild hyperthyroidism, 30 to 40 mg for moderately severe hyperthyroidism, and 60 mg for severe hyperthyroidism, divided into 3 doses at 8-hour intervals. The maintenance dosage is 5 to 15 mg daily.
PediatricInitially, the daily dosage is 0.4 mg/kg of body weight divided into 3 doses and given at 8-hour intervals. The maintenance dosage is approximately 1/2 of the initial dose.
Major adverse reactions (which occur with much less frequency than the minor adverse reactions) include inhibition of myelopoieses (agranulocytosis, granulocytopenia, thrombocytopenia, and aplastic anemia), drug fever, a lupus-like syndrome, insulin autoimmune syndrome (which can result in hypoglycemic coma), hepatitis (jaundice may persist for several weeks after discontinuation of the drug), periarteritis, and hypoprothrombinemia. Nephritis occurs very rarely.
Minor adverse reactions include skin rash, urticaria, nausea, vomiting, epigastric distress, arthralgia, paresthesia, loss of taste, abnormal loss of hair, myalgia, headache, pruritus, drowsiness, neuritis, edema, vertigo, skin pigmentation, jaundice, sialadenopathy, and lymphadenopathy.
DRUG INTERACTIONS Anticoagulants (Oral)Due to potential inhibition of vitamin K activity by methimazole, the activity of oral anticoagulants (e.g., warfarin) may be increased; additional monitoring of PT/INR should be considered, especially before surgical procedures.
β-Adrenergic Blocking AgentsHyperthyroidism may cause an increased clearance of beta blockers with a high extraction ratio. A dose reduction of beta-adrenergic blockers may be needed when a hyperthyroid patient becomes euthyroid.
Digitalis GlycosidesSerum digitalis levels may be increased when hyperthyroid patients on a stable digitalis glycoside regimen become euthyroid; a reduced dosage of digitalis glycosides may be needed.
TheophyllineTheophylline clearance may decrease when hyperthyroid patients on a stable theophylline regimen become euthyroid; a reduced dose of theophylline may be needed.
Tapazole is prescribed in the management of hyperthyroidism and thyrotoxicosis, in the medical management of goiter, and in the preparation of patients for thyroidectomy or other thyroid-related surgery. It belongs to the antithyroid category within broader endocrine and thyroid therapy. The structured indication section below this introduction lists each registered use in the markets where Tapazole is authorised.
Tapazole contains thiamazole, an antithyroid agent used in endocrine and thyroid therapy. The same molecule is known internationally as methimazole and circulates worldwide under several different brand names. Whether labelled as thiamazole or methimazole on local packaging, the underlying active ingredient is the same, although regulatory status and brand availability differ from one country to another.
Tapazole is registered in six countries: the United States, Canada, Italy, Lebanon, the Philippines, and Thailand. Outside this short list the specific brand is generally not encountered, although thiamazole — also called methimazole — is widely available in regulated markets under other brand names. If your country is not on this list, a local pharmacist can confirm whether a thiamazole-containing product is available.
Thiamazole, also marketed internationally as methimazole, is sold under several brand names worldwide. Other antithyroid molecules also exist within the same therapeutic class, although they are not freely interchangeable — molecules within a class can differ meaningfully in clinical positioning. To identify a local thiamazole-containing product, search the active ingredient on Pill2Trip or ask a pharmacist in your destination country.
Yes. Antithyroid therapy is calibrated to a patient's thyroid function, concurrent medications, and individual circumstances, and is generally monitored over time rather than self-managed. This is particularly relevant for travellers and people relocating between countries, since prescription requirements, available brands, and laboratory follow-up arrangements vary across regulatory regimes. Any decision to start, stop, switch, or substitute thiamazole should involve a healthcare provider.
